PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health 🔮 PULSE predicts: fades by tomorrow

Deaths in Brazil raise concerns about India’s dengue vaccine, DengiAll

Brazil has suspended the use of the Butantan-DV vaccine following reports of two deaths and several adverse reactions.

7sources
7articles
5velocity
+0%since first seen
104d agofirst detected

🌍 Cross-language spread

This story first appeared in 🇧🇷 Portuguese coverage — 58 minutes before PULSE detected it in English news.

🇬🇧 English Jun 16, 13:07 UTC
🇧🇷 Portuguese Jun 16, 12:09 UTC · Agência Brasil

Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Health authorities in Brazil have temporarily discontinued the use of the Butantan-DV dengue vaccine. This action follows reports of two deaths and numerous cases presenting with warning signs after administration of the vaccine. Consequently, officials have initiated a recall of specific batches currently in circulation.

Coverage from The Star, The Hindu, and Valor International highlights the suspension and the resulting investigation. Anvisa is establishing a panel of experts to conduct an epidemiological review of the occurrences, according to official reports from the Brazilian government. Insights IAS and Outbreak News Today indicate that the development has prompted international scrutiny regarding regional dengue immunization efforts.

Future developments will depend on the findings of the expert panel formed by Anvisa. The investigation is tasked with determining the nature of the reported reactions and the safety profile of the Butantan-DV vaccine. Coverage does not yet specify when the suspension might be lifted or what long-term impact the review will have on vaccination programs.

Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 102d ago.

Quick answers

Why has the vaccination program been halted?

Brazil suspended the vaccine following reports of two deaths and multiple cases with warning signs after the vaccine was administered.

What is the next step for the vaccine investigation?

Anvisa is organizing a panel of experts to perform an epidemiological investigation into the vaccine and the reported adverse events.

Is the vaccine being removed from circulation?

Yes, officials have suspended the use of the vaccine and initiated a recall of existing batches.

Coverage (7)

Topics

Brazil Butantan-DV Anvisa Dengue Vaccine Public Health

Related trends

\n \n \n \n \n \n \n